These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 10027003)

  • 1. Mechanisms of development of multiple endocrine neoplasia type 2 and Hirschsprung's disease by ret mutations.
    Takahashi M; Asai N; Iwashita T; Murakami H; Ito S
    Recent Results Cancer Res; 1998; 154():229-36. PubMed ID: 10027003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease.
    Carlomagno F; Melillo RM; Visconti R; Salvatore G; De Vita G; Lupoli G; Yu Y; Jing S; Vecchio G; Fusco A; Santoro M
    Endocrinology; 1998 Aug; 139(8):3613-9. PubMed ID: 9681515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-segregation of MEN2 and Hirschsprung's disease: the same mutation of RET with both gain and loss-of-function?
    Takahashi M; Iwashita T; Santoro M; Lyonnet S; Lenoir GM; Billaud M
    Hum Mutat; 1999; 13(4):331-6. PubMed ID: 10220148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RET activation by germline MEN2A and MEN2B mutations.
    Borrello MG; Smith DP; Pasini B; Bongarzone I; Greco A; Lorenzo MJ; Arighi E; Miranda C; Eng C; Alberti L
    Oncogene; 1995 Dec; 11(11):2419-27. PubMed ID: 8570194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype.
    Ito S; Iwashita T; Asai N; Murakami H; Iwata Y; Sobue G; Takahashi M
    Cancer Res; 1997 Jul; 57(14):2870-2. PubMed ID: 9230192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular analysis of the ret and GDNF genes in a family with multiple endocrine neoplasia type 2A and Hirschsprung disease.
    Borrego S; Eng C; Sánchez B; Sáez ME; Navarro E; Antiñolo G
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3361-4. PubMed ID: 9745455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Full activation of MEN2B mutant RET by an additional MEN2A mutation or by ligand GDNF stimulation.
    Bongarzone I; Vigano E; Alberti L; Borrello MG; Pasini B; Greco A; Mondellini P; Smith DP; Ponder BA; Romeo G; Pierotti MA
    Oncogene; 1998 May; 16(18):2295-301. PubMed ID: 9620546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of tyrosine residues that are essential for transforming activity of the ret proto-oncogene with MEN2A or MEN2B mutation.
    Iwashita T; Asai N; Murakami H; Matsuyama M; Takahashi M
    Oncogene; 1996 Feb; 12(3):481-7. PubMed ID: 8637703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A mutation in the RET proto-oncogene in Hirschsprung's disease affects the tyrosine kinase activity associated with multiple endocrine neoplasia type 2A and 2B.
    Cosma MP; Panariello L; Quadro L; Dathan NA; Fattoruso O; Colantuoni V
    Biochem J; 1996 Mar; 314 ( Pt 2)(Pt 2):397-400. PubMed ID: 8670046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncological implications of RET gene mutations in Hirschsprung's disease.
    Sijmons RH; Hofstra RM; Wijburg FA; Links TP; Zwierstra RP; Vermey A; Aronson DC; Tan-Sindhunata G; Brouwers-Smalbraak GJ; Maas SM; Buys CH
    Gut; 1998 Oct; 43(4):542-7. PubMed ID: 9824583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological effects of the dual phenotypic Janus mutation of ret cosegregating with both multiple endocrine neoplasia type 2 and Hirschsprung's disease.
    Arighi E; Popsueva A; Degl'Innocenti D; Borrello MG; Carniti C; Perälä NM; Pierotti MA; Sariola H
    Mol Endocrinol; 2004 Apr; 18(4):1004-17. PubMed ID: 14715928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular heterogeneity of RET loss of function in Hirschsprung's disease.
    Carlomagno F; De Vita G; Berlingieri MT; de Franciscis V; Melillo RM; Colantuoni V; Kraus MH; Di Fiore PP; Fusco A; Santoro M
    EMBO J; 1996 Jun; 15(11):2717-25. PubMed ID: 8654369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Putting the bits and pieces of the RET proto-oncogene puzzle together.
    Gagel RF
    Bone; 1995 Aug; 17(2 Suppl):13S-16S. PubMed ID: 8579892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype.
    Carlomagno F; Salvatore G; Cirafici AM; De Vita G; Melillo RM; de Franciscis V; Billaud M; Fusco A; Santoro M
    Cancer Res; 1997 Feb; 57(3):391-5. PubMed ID: 9012462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Occurrence of MEN 2a in familial Hirschsprung's disease: a new indication for genetic testing of the RET proto-oncogene.
    Decker RA; Peacock ML
    J Pediatr Surg; 1998 Feb; 33(2):207-14. PubMed ID: 9498388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B.
    Salvatore D; Melillo RM; Monaco C; Visconti R; Fenzi G; Vecchio G; Fusco A; Santoro M
    Cancer Res; 2001 Feb; 61(4):1426-31. PubMed ID: 11245446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines.
    Chappuis-Flament S; Pasini A; De Vita G; Ségouffin-Cariou C; Fusco A; Attié T; Lenoir GM; Santoro M; Billaud M
    Oncogene; 1998 Dec; 17(22):2851-61. PubMed ID: 9879991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of Ret-Shc-Grb2 complex induced by GDNF, MEN 2A, and MEN 2B mutations.
    Ohiwa M; Murakami H; Iwashita T; Asai N; Iwata Y; Imai T; Funahashi H; Takagi H; Takahashi M
    Biochem Biophys Res Commun; 1997 Aug; 237(3):747-51. PubMed ID: 9299438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutation analysis of the RET receptor tyrosine kinase in Hirschsprung disease.
    Angrist M; Bolk S; Thiel B; Puffenberger EG; Hofstra RM; Buys CH; Cass DT; Chakravarti A
    Hum Mol Genet; 1995 May; 4(5):821-30. PubMed ID: 7633441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C618R mutation in exon 10 of the RET proto-oncogene in a kindred with multiple endocrine neoplasia type 2A and Hirschsprung's disease.
    Caron P; Attié T; David D; Amiel J; Brousset F; Roger P; Munnich A; Lyonnet S
    J Clin Endocrinol Metab; 1996 Jul; 81(7):2731-3. PubMed ID: 8675603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.